Collectively, ASP exhibited two anti-diabetic pharmacological properties, inhibition of both α-glucosidase and SGLT2 activities and glucose lowering effects presumably targeting muscle cells in some T2DM mouse models, however, the present study failed to display a marked reduction of blood glucose levels by the administration of ASP alone to DM rodents. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.